Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanoma VJOncology 1:36 2 years ago 120 Скачать Далее
Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma AJMCtv 7:56 7 years ago 286 Скачать Далее
KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanoma VJOncology 5:54 2 years ago 373 Скачать Далее
Dr. Michael Atkins on Benefits of Adjuvant Treatment in Melanoma Targeted Oncology 1:06 8 years ago 102 Скачать Далее
Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC PeerView Oncology 38:09 4 years ago 139 Скачать Далее